Morgan Stanley’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Morgan Stanley’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,000	Closed	-$4K	–	8200
2022 Q1	$4K	Hold	5,000	–	–	﹤0.01%	7667
2021 Q4	$4K	Sell	5,000 -1,000	-17%	-$1.04K	﹤0.01%	7718
2021 Q3	$8K	Hold	6,000	–	–	﹤0.01%	7410
2021 Q2	$9K	Sell	6,000 -7,661	-56%	-$10.7K	﹤0.01%	7281
2021 Q1	$21K	Buy	13,661 +7,661	+128%	+$13.2K	﹤0.01%	6707
2020 Q4	$9K	Hold	6,000	–	–	﹤0.01%	6671
2020 Q3	$8K	Hold	6,000	–	–	﹤0.01%	6348
2020 Q2	$11K	Hold	6,000	–	–	﹤0.01%	6147
2020 Q1	$7K	Sell	6,000 -5,000	-45%	-$11.1K	﹤0.01%	6128
2019 Q4	$36K	Buy	11,000 +10,000	+1,000%	+$76.7K	﹤0.01%	5945
2019 Q3	$6K	Buy	+1,000	New	+$10.2K	﹤0.01%	6342

Other funds holding MITO

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Morgan Stanley's MITO Position: Q2 2022 in Review

Morgan Stanley sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q2 2022, closing a stake of 5,000 shares — an estimated $4K sold.

Morgan Stanley first reported a position in MITO in Q3 2019 and held it in 11 quarters. The position peaked at $36K in Q4 2019. 19 funds tracked by Wall St. Rank hold MITO as of Q2 2022.

Morgan Stanley reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q2 2022 after selling out during the quarter.
Morgan Stanley sold 5,000 Stealth BioTherapeutics Corp. ADS shares in Q2 2022, an estimated $4K.
Morgan Stanley first reported a position in Stealth BioTherapeutics Corp. ADS in Q3 2019 and held it in 11 quarters.
Morgan Stanley's Stealth BioTherapeutics Corp. ADS position peaked at $36K in Q4 2019.
19 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q2 2022.

Based on Morgan Stanley's 13F filing for Q2 2022, filed 15 Aug 2022.